delgocitinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Janus kinase inhibitors, antineoplastics 5426 1263774-59-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • delgocitinib
  • JTE-052
  • JTE-052A
  • LEO 124249
  • LEO 124249A
  • LP0133
  • corectim
Delgocitinib, a janus kinase (JAK) inhibitor, is being approved for the treatment of inflammatory skin conditions. Delgocitinib inhibited the activation of inflammatory cells, such as T cells, B cells, monocytes and mast cells, in vitro and inhibited Th1-, Th2- and Th17-type cytokine production from both T cells and non-T cells.
  • Molecular weight: 310.36
  • Formula: C16H18N6O
  • CLOGP: 0.21
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 88.91
  • ALOGS: -2.75
  • ROTB: 2

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2020 PMDA Japan Tobacco

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:50748 antipsoriatic agent
CHEBI has role CHEBI:59010 antiseborrheic drug
CHEBI has role CHEBI:76617 abl inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D11046 KEGG_DRUG
C5226741 UMLSCUI
CHEBI:167600 CHEBI
FHX PDB_CHEM_ID
CHEMBL4297507 ChEMBL_ID
DB16133 DRUGBANK_ID
C000621572 MESH_SUPPLEMENTAL_RECORD_UI
50914062 PUBCHEM_CID
9619 IUPHAR_LIGAND_ID
10574 INN_ID
9L0Q8KK220 UNII

Pharmaceutical products:

None